Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

JR-14a shows potent neuroprotective effect in stroke models

Feb. 10, 2022

Eisai divulges new OX2 receptor agonists for narcolepsy

Feb. 9, 2022

Korean researchers synthesize PDE5A and HDAC6 dual inhibitors for Alzheimer's

Feb. 9, 2022

Non-muscle-targeted AAV8/DC190-ASM gene therapy for treating limb girdle muscular dystrophy 2B

Feb. 9, 2022

New PET ligand allows in vivo pharmacological evaluation of agents targeting mutant HTT expression

Feb. 9, 2022

Researchers divulge SSTR4 agonists for treatment of pain

Feb. 8, 2022

Mindset to initiate proof-of-concept preclinical studies on Family 3 compounds for cognitive benefit

Feb. 7, 2022

Parkinson's UK and Domainex collaborate to target neuroinflammation to slow Parkinson's disease

Feb. 7, 2022

Selenium mediates neurogenesis after hippocampal injury

Feb. 7, 2022

Tactogen patents 5-HT1B receptor agonists and MAO-A inhibitors

Feb. 7, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
GSK’s newly acquired Jideytro wins FDA nod in NSCLC
BioWorld
About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...